Abstract:Sudden cardiac death is one of the most important causes of death worldwide. Advancements in medical treatment, percutaneous interventions, and device therapy (ICD and CRTD) showed consistent reduction in mortality, mainly in survivors of SCD and in patients with ischemic cardiomyopathy and depressed left ventricular function. Patients with non-ischemic cardiomyopathies, mildly reduced LV function, and channelopathies have increased risk for SCD. Identifying the subgroup of these patients before they experience life-threatening or fatal events is essential to further improve outcomes. In this review, we aimed to summarize the current knowledge for risk stratification and primary prevention, to describe the gaps in evidence, and to discuss future directions for screening and treating patients at risk for SCD. PURPOSE OF REVIEW: The purpose of this review is to provide a comprehensive description of the etiologies of sudden cardiac death, risk stratification strategies, and to describe the current medical and interventional therapies. We aimed to discuss the current gaps in our knowledge of primary prevention of SCD and to review novel approaches and interventions. RECENT FINDINGS: The incidence of SCD has decreased in the last two decades due to improved pharmacological treatment and ICD implantation in SCD survivors and in patients with reduced left ventricular function and ischemic cardiomyopathy. The efficacy of ICD in patients with non-ischemic cardiomyopathy is challenged by new findings from the DANISH trial. Catheter ablation is new emerging strategy to prevent SCD in patients with scar relater or PVC-triggered ventricular arrhythmias. Despite the new treatments, SCD is still a major burden. ICD remains the cornerstone for patients with ischemic cardiomyopathy, whereas appropriate risk stratification of the patients with non-ischemic cardiomyopathy and channelopathies is needed to further improve outcomes. The future of ablation as the treatment and prevention of SCD remains to be studied.

The Genetic Basis of Sudden Cardiac Death: From Diagnosis to Emerging Genetic Therapies

Opportunities for sudden death prevention: Directions for new clinical and basic research

Arrhythmic Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction: Mechanisms, Genetics, and Future Directions

Cardiogenetics: the role of genetic testing for inherited arrhythmia syndromes and sudden death

Incomplete Penetrance and Variable Expressivity: Hallmarks in Channelopathies Associated with Sudden Cardiac Death

Precision Medicine and Cardiac Channelopathies: Human iPSCs Take the Lead

Trans-Atlantic Differences in Approach to Sudden Death Prevention in Patients With Hypertrophic Cardiomyopathy

Genetic Causes of Sudden Cardiac Arrest in the Community

The impact of damaging epilepsy and cardiac genetic variant burden in sudden death in the young

Inherited conditions of arrhythmia: translating disease mechanisms to patient management

Modifier genes for sudden cardiac death

For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death

The present situation and prospects of study on molecular autopsy of sudden death caused by genetic arrhythmia

Cardiac channelopathies in pediatrics: a genetic update

Primary Electrical Heart Disease—Principles of Pathophysiology and Genetics

Prediction and Prevention of Sudden Death in the Brugada Syndrome

SVAD: A genetic database curates non-ischemic sudden cardiac death-associated variants

Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies

Pathogenesis and Clinical Characteristics of Hereditary Arrhythmia Diseases

Ion Channel Disorders and Sudden Cardiac Death

Cardiomyopathy and Sudden Cardiac Death: Bridging Clinical Practice with Cutting-Edge Research